Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severity and phenotypes of dyspnea in asthma: Impact of comorbidities.
Bousso A, Chuffart C, Leroy M, Gicquello A, Cottereau A, Hennegrave F, Beurnier A, Stoup T, Pereira S, Morelot-Panzini C, Taille C, Bautin N, Fry S, Perez T, Garcia G, Chenivesse C. Bousso A, et al. Among authors: fry s. Respir Med. 2023 May 20:107276. doi: 10.1016/j.rmed.2023.107276. Online ahead of print. Respir Med. 2023. PMID: 37217082
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study.
Guilleminault L, Camus C, Raherison-Semjen C, Capdepon A, Bourdin A, Bonniaud P, Fry S, Devouassoux G, Blanc FX, Pison C, Dupin C, Khayath N, Courdeau J, Valcke-Brossollet J, Nocent-Ejnaini C, Rolland F, Lamandi C, Proust A, Ozier A, Portel L, Gaspard W, Roux-Claude P, Beurnier A, Martinez S, Dot JM, Hennegrave F, Vignal G, Auvray E, Paleiron N, Just N, Miltgen J, Russier M, Olivier C, Taillé C, Didier A. Guilleminault L, et al. Among authors: fry s. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231202749. doi: 10.1177/17534666231202749. Ther Adv Respir Dis. 2023. PMID: 37966015 Free PMC article.
Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trial.
Valery S, Simon-Tillaux N, Devouassoux G, Bonniaud P, Beurnier A, Boudjemaa A, Chenivesse C, Bourdin A, Gauquelin L, Guillo S, Taillé C, Estellat C; RAMSES Study Group. Valery S, et al. J Allergy Clin Immunol. 2024 Oct;154(4):922-932. doi: 10.1016/j.jaci.2024.05.023. Epub 2024 Jun 6. J Allergy Clin Immunol. 2024. PMID: 38848878 Free article. Clinical Trial.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Jackson DJ, et al. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Free article. Clinical Trial.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
481 results